The History and Development of HER2 Inhibitors

The History and Development of HER2 Inhibitors

HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mai...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2023-10, Vol.16 (10), p.1450
Hauptverfasser: Xia, Xiaohui, Gong, Chen, Zhang, Yinan, Xiong, Huihua
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
Antibody-drug conjugates
Breast cancer
cancer
Cancer therapies
Chemotherapy
Colorectal cancer
FDA approval
Gastric cancer
HER2 inhibitors
History
Kinases
Medical research
Monoclonal antibodies
Ovarian cancer
Product development
Review
Tumors
tyrosine kinase inhibitors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:HER2 is highly expressed in a variety of malignant tumors and affects the prognosis of patients, making it a highly sensitive target for cancer therapy. Since the approval of the first HER2 inhibitor, trastuzumab, in 1998, HER2-targeted drugs have rapidly evolved. Currently, targeting HER2 drugs mainly include monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). This article reviews the development of HER2 inhibitors for various tumors over the past 20 years.
ISSN:1424-8247
1424-8247
DOI:10.3390/ph16101450